A new research study by RCSI found that 15.8% of male medical students never felt intimidated during surgical placements, compared to 6.9% of female students. The study suggests that a lack of role models in surgery is a major deterrent for women in pursuing a career in surgery.
A €7 million Parkinson's research project, PD-MitoQUANT, will be coordinated by RCSI to deepen understanding of the disease and develop new treatments. The project aims to increase knowledge of how cells in the brain become damaged in Parkinson's, with a focus on mitochondria.
A pre-clinical trial of InnovoSep has demonstrated potential to stop sepsis-causing bacteria from triggering organ damage. The drug also showed effectiveness in preventing sepsis progression and treating advanced sepsis.
The partnership will provide insights into disease progression and responses to treatment, helping clinicians identify risk factors and inform personalized treatment planning. The project's goal is to promote proactive and tailored care to prevent disease deterioration and improve patient outcomes.
Patients who receive a kidney transplant are at increased risk of skin cancer, with the rate rising after stopping anti-rejection medications, according to a study. The study found that skin cancer rates fell during periods of transplant failure but remained higher than pre-transplant patients on dialysis.
Researchers at RCSI have developed a new treatment for osteomyelitis using a copper-rich glass implant. The implant attracts blood vessels and bone cells, accelerating bone repair and preventing bacterial growth. This breakthrough treatment has the potential to reduce antibiotic use and improve outcomes for patients with bone infections.
A team of RCSI researchers has developed a new treatment for tuberculosis (TB) that could be used to treat hundreds of thousands of patients. The treatment uses all-trans retinoic acid, which has shown promise in previous studies and can help reduce bacteria and lung damage.
A large-scale genetic study has identified 11 new genes associated with epilepsy, which may inform the development of new treatments. The research, led by RCSI researchers, compared DNA samples from over 15,000 people with and without epilepsy, tripling the number of known genetic associations.
Research from RCSI found that one quarter of individuals who attempted or died by suicide had problems with basic sensory experiences, such as hearing or seeing things that aren't real. This dysfunction can predict suicidal behavior and offers new avenues for treatment and suicide prevention.
Researchers at RCSI are developing six prototypes to remove Contaminants of Emerging Concerns from drinking water and wastewater in rural India. The project aims to provide clean drinking water to 2.1 billion people without access to safe sources.
The €13.6 million FutureNeuro centre will focus on understanding brain structure and function to transform the patient journey for people with neurological diseases. Outcomes include improved diagnostics, precision medicine, point-of-care technology and new treatments.
A new study by RCSI found that older hospital patients are 72% more likely to receive inappropriate prescriptions, regardless of other factors. The research highlights the need for healthcare providers to consider the potential adverse effects of hospitalization on prescribing appropriate medication for older adults.
The partnership aims to provide a voice-based user interface for an existing Epilepsy Patient Portal, allowing patients to co-author their electronic patient record. This enhanced system will facilitate real-time reporting of health information using the patients' voice, making it easier for clinicians and more useful for patients.
Researchers at RCSI have discovered that chromosomal instability can predict which patients will benefit from the colorectal cancer drug Avastin. Patients with intermediate-to-high levels of chromosomal instability responded better to Avastin treatment, while those with low levels of chromosomal instability benefited less.
Researchers have discovered a marker that can help identify patients with severe asthma who are likely to respond well to new treatments. The marker targets inflammatory cells called eosinophils, which play a key role in the condition.
A clinical trial found that using an anti-inflammatory agent during surgery can reduce inflammation and tumor cell growth, potentially improving cancer outcomes. The study tested a solution containing Taurolidine in patients undergoing surgery for colon cancer.
Researchers at RCSI and Trinity College Dublin have discovered how the body clock regulates inflammatory response in macrophages, a key immune cell. This study may lead to targeted treatments at specific times of the day to alleviate excess inflammation in conditions like asthma, arthritis, and cardiovascular disease.
RCSI and Bayer are working together to create new, tailored treatments for people with severe haemophilia. The goal is to promote blood clotting with increased precision, improving the quality of life for those affected by this condition.
A new partnership aims to explore the use of cannabidiol (CBD) and other non-psychoactive molecules from the cannabis plant to reduce seizures in patients with drug-resistant epilepsies. The research will also optimize the effectiveness of this approach to treat epilepsy, offering a potential new horizon for severe disabling seizures.
A ground-breaking partnership between Congenica and FutureNeuro aims to improve diagnosis accuracy in genetic epilepsy. The new software will work with electronic health records to provide clinicians and patients with tailored treatment decisions.